REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.35
Bid: 1.30
Ask: 1.40
Change: 0.05 (3.85%)
Spread: 0.10 (7.692%)
Open: 1.30
High: 1.35
Low: 1.30
Prev. Close: 1.30
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Confirmation of Twitter account

16 Apr 2020 07:00

RNS Number : 8079J
Physiomics PLC
16 April 2020
 

16 April 2020

 

Physiomics plc

("Physiomics") or (the "Company")

 

Confirmation of Twitter account

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, would like to note that its only official twitter account is @Physiomics.

 

It has come to the Company's attention that a twitter account with a similar name, @Physiomics1, which was set up in February this year, has been tweeting and retweeting content relating to the Company. This account is not endorsed by and does not come from the Company and we have requested that it be closed.

 

The Company will continue to keep shareholders update on any material developments in the ordinary course, in accordance with its regulatory obligations.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics® is an oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

 

For more information please visit:

www.physiomics-plc.com

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFELLFBZLBBBB
Date   Source Headline
7th Feb 20119:42 amRNSIssue of Options
24th Dec 20109:06 amRNSDirector's Notification
13th Dec 201011:07 amRNSResult of AGM
6th Dec 20107:00 amRNSDirectorate Change
15th Nov 20103:23 pmRNSNew Project and Grant Funding
15th Nov 20107:10 amRNSFinal Results for the year ended 30 June 2010
22nd Sep 20103:10 pmRNSRecent Price Movements
31st Aug 20107:01 amRNSJoint Services Alliance with Jubilant Biosys
14th May 201012:08 pmRNSRecent Price Movements and Press Speculation
16th Mar 20107:00 amRNSCollaboration with Sareum, the ICR and CRT
1st Mar 20107:00 amRNSHalf Yearly Report
8th Feb 20104:22 pmRNSHolding(s) in Company
29th Jan 20102:20 pmRNSTotal Voting Rights
29th Jan 20102:17 pmRNSHolding(s) in Company
22nd Jan 20101:14 pmRNSIssue of Equity
29th Dec 200910:53 amRNSResult of AGM
18th Dec 20091:06 pmRNSConversion of Loan Note
14th Dec 200912:46 pmRNSIssue of Equity
9th Dec 20097:47 amRNSHolding(s) in Company
4th Dec 200911:47 amRNSIssue of Equity
25th Nov 20099:16 amRNSHolding(s) in Company
19th Nov 20099:03 amRNSHolding(s) in Company
16th Nov 20094:50 pmRNSHolding(s) in Company
16th Nov 20097:00 amRNSPhysiomics Presentation
6th Nov 20094:30 pmRNSHolding(s) in Company
5th Nov 20094:22 pmRNSHolding(s) in Company
27th Oct 20094:18 pmRNSHolding(s) in Company
27th Oct 20099:35 amRNSHolding(s) in Company
23rd Oct 20094:23 pmRNSHolding(s) in Company
21st Oct 20099:06 amRNSHolding(s) in Company
20th Oct 20094:01 pmRNSHolding(s) in Company
20th Oct 20093:59 pmRNSHolding(s) in Company
16th Oct 20094:30 pmRNSRecent Price Movements
1st Oct 20093:02 pmRNSTrading Statement
18th Sep 200910:02 amRNSHolding(s) in Company
11th Sep 20093:52 pmRNSHolding(s) in Company
8th Sep 200912:37 pmRNSHolding(s) in Company - Replacement
7th Sep 20094:35 pmRNSHolding(s) in Company
3rd Sep 20099:12 amRNSHolding(s) in Company
28th Aug 20097:56 amRNSTotal Voting Rights
17th Aug 200910:01 amRNSHolding(s) in Company
6th Aug 20094:23 pmRNSConversion of Debt into Equity
24th Jul 20098:01 amRNSHolding(s) in Company
6th Jul 200911:52 amRNSHolding(s) in Company
2nd Jul 20097:53 amRNSHolding(s) in Company
26th Jun 20097:58 amRNSHolding(s) in Company
23rd Jun 20097:00 amRNSUpdate on EC funded TEMPO project
23rd Apr 20094:34 pmRNSHolding(s) in Company
22nd Apr 20094:43 pmRNSHolding(s) in Company
22nd Apr 20094:43 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.